RxDoctor Payments Data

Douglas Long, MD

Ophthalmology · Waukesha, WINPI 1255368528

Payments from drug & device makers

$561in general payments, 2019–2025

Across 17 payments — averaging $32.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$268
  • Rxsight Inc$55
  • AbbVie$49
  • Rayner Intraocular Lenses Limited$44
  • Bausch & Lomb Americas Inc.$40
  • Genentech USA, Inc.$27
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$561 in reported general payments places this provider in the 55th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$278,252
Medicare patients
685
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$21,608
Prednisolone Acetate315$16,879
Ketorolac Tromethamine328$16,033
SimbrinzaBrinzolamide/Brimonidine Tart21$5,530
Latanoprost403$3,980
ValacyclovirValacyclovir Hcl16$2,258
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat101$1,550
Timolol Maleate37$595
Brimonidine Tartrate18$467
Ciprofloxacin Hcl24$248
ErythromycinErythromycin Base16$169
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$49$21,60812 claims
AlconSimbrinza$268$5,53021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Waukesha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →